Fresenius Medical Care AG & Co. KGaA ("the company" or "Fresenius Medical Care"), the world's largest provider of dialysis products and services, today announced its intention to sell US$500 million of senior unsecured notes due 2021 issued by Fresenius Medical Care US Finance, Inc. and €300 million of senior unsecured notes due 2021 issued by FMC Finance VII S.A. (together with the US$ senior notes "the senior notes"). Both issuers are wholly owned subsidiaries of the company.
The senior notes will be guaranteed on a senior basis jointly and severally by the company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH.
The senior notes will be offered through a private placement directed to institutional investors. There will be no public offering of the senior notes. Proceeds from the offering will be used to repay indebtedness, for acquisitions including the company's recently announced acquisition of Euromedic's dialysis service business and for general corporate purposes to support the renal products and services business.
The proposed offering will not be registered under the Securities Act of 1933. The senior notes will be offered in the United States to "qualified institutional buyers" pursuant to the exemption from registration under Rule 144A of the Securities Act, and the offering will be made in an "offshore transaction" pursuant to Regulation S under the Securities Act.
Bariatric surgery outperforms GLP-1 medications in protecting kidney function